Press Releases Harmony Biosciences Holdings, Inc.

Equities

HRMY

US4131971040

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2025-05-22 pm EDT			5-day change	1st Jan Change
34.13 ^USD	-1.07%		+2.22%	-0.81%

May. 15	Mizuho Raises Price Target on Harmony Biosciences to $48 From $44, Keeps Outperform Rating	MT
May. 06	Harmony Biosciences Q1 Adjusted Earnings, Revenue Increase; 2025 Sales Outlook Reiterated	MT

Press Releases

Harmony Biosciences : HRMY Q1 2025 Earnings Presentation FINAL	May. 06	PU
Harmony Biosciences : HRMY Corporate Presentation May 6, 2025 FINAL	May. 06	PU
Harmony Biosciences Reports Strong Q1 2025 Financial Results, Highlights Advancement of Its Pipeline and Upcoming Catalysts, and Reaffirms 2025 Revenue Guidance	May. 06	BU
Harmony Biosciences to Report First Quarter 2025 Financial Results on May 6, 2025	Apr. 29	BU
Harmony Biosciences Presents Promising Open-Label Extension Data of ZYN002 in Fragile X Syndrome	Apr. 08	BU
Harmony Biosciences Appoints Biotech Leader Ron Philip to Its Board of Directors	Apr. 03	BU
Harmony Biosciences to Participate in 24th Annual Needham Virtual Healthcare Conference	Mar. 26	BU
Harmony Biosciences Names Adam Zaeske as Chief Commercial Officer to Lead the Next Phase of Commercial Growth as Its Portfolio Expands	Mar. 24	BU
HRMY Investors Have Opportunity to Join Harmony Biosciences Holdings, Inc. Fraud Investigation with the Schall Law Firm	Mar. 21	BU
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harmony Biosciences Holdings, Inc. - HRMY	Mar. 17	PR
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harmony Biosciences Holdings, Inc. - HRMY	Mar. 11	PR
Harmony Biosciences to Participate in Upcoming Investor Conferences	Mar. 04	BU
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harmony Biosciences Holdings, Inc. - HRMY	Mar. 03	PR
Harmony Biosciences : Portillo’s Affirms Commitment to Shareholder Value	Mar. 02	PU
Harmony Biosciences Reports Strong 2024 Financial Results and Reiterates 2025 Net Revenue Guidance, Highlights 2025 Catalysts in Sleep, Wake and Fragile X Syndrome Development Programs	Feb. 26	AQ
Harmony Biosciences Reports Strong 2024 Financial Results and Reiterates 2025 Net Revenue Guidance; Highlights 2025 Catalysts in Sleep/Wake and Fragile X Syndrome Development Programs	Feb. 25	BU
Harmony Biosciences Provides Update on the Status of the Supplemental New Drug Application for Pitolisant in Idiopathic Hypersomnia	Feb. 19	BU
Harmony Biosciences to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025	Feb. 18	BU
Harmony Biosciences Reports Strong 2024 Revenues, Provides 2025 Revenue Guidance and Highlights Key Pipeline Catalysts	Jan. 13	BU
HARMONY BIOSCIENCES TO PRESENT AT THE 43RD ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE	Dec. 18	PR
HARMONY BIOSCIENCES TO PARTICIPATE IN OPPENHEIMER MOVERS IN RARE DISEASE SUMMIT	Dec. 03	PR
HARMONY BIOSCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES	Nov. 21	PR
Harmony Biosciences : Statement of Changes in Beneficial Ownership - Form 4	Nov. 05	PU
Axonis Therapeutics Announces $115 Million Series a Financing	24-10-31	AQ
Harmony Biosciences Holdings, Inc. Announces Pricing of Public Offering of Common Stock by Selling Shareholders	24-10-30	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Harmony Biosciences Holdings, Inc.

Equities

HRMY

US4131971040

Pharmaceuticals

Press Releases

Filters